Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer

Minna M. Tanner, Seija Grenman, Anjila Koul, Oskar Johannsson, Paul Meltzer, Tanja Pejovic, Åke Borg, Jorma J. Isola

Research output: Contribution to journalArticle

285 Citations (Scopus)

Abstract

DNA amplification at chromosomal region 20q12-q13, which is common in breast cancer, has recently been described also in ovarian tumors. We studied the amplification of the recently identified candidate oncogenes in this region in 24 sporadic, 3 familial and 4 hereditary ovarian carcinomas, and in 8 ovarian cancer cell lines. High-level amplification of at least one of the five nonsyntenic regions at 20q12-q13.2 was found in 13 sporadic (54%) and in all four hereditary tumors. Typically, two or more distinct amplicons (separated by nonamplified DNA) were found coamplified in various combinations. The regions defined by the AIB1 and PTPN1 genes (at 20q12 and 20q13.1, respectively) were amplified in 25% and 29% of the sporadic tumors, also without simultaneous coamplification of other regions. Amplification of AIB1 (asteroid receptor coactivator gene) was associated with estrogen receptor positivity in sporadic ovarian carcinomas (P = 0.01) and showed a tendency to correlate with poor survival of patients. Of the genes amplified in breast cancer, the BTAK gene was amplified in 21%, the MYBL2 gene in 17%, and the ZNF217 gene in 12.5% of the sporadic tumors. The high frequency of gene amplification at 20q12-q13.2 suggests that the genes amplified therein may play a central role in the pathogenesis of sporadic and hereditary ovarian carcinoma.

Original languageEnglish (US)
Pages (from-to)1833-1839
Number of pages7
JournalClinical Cancer Research
Volume6
Issue number5
StatePublished - May 2000
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Genes
Carcinoma
Neoplasms
Minor Planets
Breast Neoplasms
Gene Amplification
Neoplasm Genes
DNA
Oncogenes
Estrogen Receptors
Cell Line
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tanner, M. M., Grenman, S., Koul, A., Johannsson, O., Meltzer, P., Pejovic, T., ... Isola, J. J. (2000). Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clinical Cancer Research, 6(5), 1833-1839.

Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. / Tanner, Minna M.; Grenman, Seija; Koul, Anjila; Johannsson, Oskar; Meltzer, Paul; Pejovic, Tanja; Borg, Åke; Isola, Jorma J.

In: Clinical Cancer Research, Vol. 6, No. 5, 05.2000, p. 1833-1839.

Research output: Contribution to journalArticle

Tanner, MM, Grenman, S, Koul, A, Johannsson, O, Meltzer, P, Pejovic, T, Borg, Å & Isola, JJ 2000, 'Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer', Clinical Cancer Research, vol. 6, no. 5, pp. 1833-1839.
Tanner MM, Grenman S, Koul A, Johannsson O, Meltzer P, Pejovic T et al. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clinical Cancer Research. 2000 May;6(5):1833-1839.
Tanner, Minna M. ; Grenman, Seija ; Koul, Anjila ; Johannsson, Oskar ; Meltzer, Paul ; Pejovic, Tanja ; Borg, Åke ; Isola, Jorma J. / Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. In: Clinical Cancer Research. 2000 ; Vol. 6, No. 5. pp. 1833-1839.
@article{5537dfae36e34517a04d575e18cb5da7,
title = "Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer",
abstract = "DNA amplification at chromosomal region 20q12-q13, which is common in breast cancer, has recently been described also in ovarian tumors. We studied the amplification of the recently identified candidate oncogenes in this region in 24 sporadic, 3 familial and 4 hereditary ovarian carcinomas, and in 8 ovarian cancer cell lines. High-level amplification of at least one of the five nonsyntenic regions at 20q12-q13.2 was found in 13 sporadic (54{\%}) and in all four hereditary tumors. Typically, two or more distinct amplicons (separated by nonamplified DNA) were found coamplified in various combinations. The regions defined by the AIB1 and PTPN1 genes (at 20q12 and 20q13.1, respectively) were amplified in 25{\%} and 29{\%} of the sporadic tumors, also without simultaneous coamplification of other regions. Amplification of AIB1 (asteroid receptor coactivator gene) was associated with estrogen receptor positivity in sporadic ovarian carcinomas (P = 0.01) and showed a tendency to correlate with poor survival of patients. Of the genes amplified in breast cancer, the BTAK gene was amplified in 21{\%}, the MYBL2 gene in 17{\%}, and the ZNF217 gene in 12.5{\%} of the sporadic tumors. The high frequency of gene amplification at 20q12-q13.2 suggests that the genes amplified therein may play a central role in the pathogenesis of sporadic and hereditary ovarian carcinoma.",
author = "Tanner, {Minna M.} and Seija Grenman and Anjila Koul and Oskar Johannsson and Paul Meltzer and Tanja Pejovic and {\AA}ke Borg and Isola, {Jorma J.}",
year = "2000",
month = "5",
language = "English (US)",
volume = "6",
pages = "1833--1839",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer

AU - Tanner, Minna M.

AU - Grenman, Seija

AU - Koul, Anjila

AU - Johannsson, Oskar

AU - Meltzer, Paul

AU - Pejovic, Tanja

AU - Borg, Åke

AU - Isola, Jorma J.

PY - 2000/5

Y1 - 2000/5

N2 - DNA amplification at chromosomal region 20q12-q13, which is common in breast cancer, has recently been described also in ovarian tumors. We studied the amplification of the recently identified candidate oncogenes in this region in 24 sporadic, 3 familial and 4 hereditary ovarian carcinomas, and in 8 ovarian cancer cell lines. High-level amplification of at least one of the five nonsyntenic regions at 20q12-q13.2 was found in 13 sporadic (54%) and in all four hereditary tumors. Typically, two or more distinct amplicons (separated by nonamplified DNA) were found coamplified in various combinations. The regions defined by the AIB1 and PTPN1 genes (at 20q12 and 20q13.1, respectively) were amplified in 25% and 29% of the sporadic tumors, also without simultaneous coamplification of other regions. Amplification of AIB1 (asteroid receptor coactivator gene) was associated with estrogen receptor positivity in sporadic ovarian carcinomas (P = 0.01) and showed a tendency to correlate with poor survival of patients. Of the genes amplified in breast cancer, the BTAK gene was amplified in 21%, the MYBL2 gene in 17%, and the ZNF217 gene in 12.5% of the sporadic tumors. The high frequency of gene amplification at 20q12-q13.2 suggests that the genes amplified therein may play a central role in the pathogenesis of sporadic and hereditary ovarian carcinoma.

AB - DNA amplification at chromosomal region 20q12-q13, which is common in breast cancer, has recently been described also in ovarian tumors. We studied the amplification of the recently identified candidate oncogenes in this region in 24 sporadic, 3 familial and 4 hereditary ovarian carcinomas, and in 8 ovarian cancer cell lines. High-level amplification of at least one of the five nonsyntenic regions at 20q12-q13.2 was found in 13 sporadic (54%) and in all four hereditary tumors. Typically, two or more distinct amplicons (separated by nonamplified DNA) were found coamplified in various combinations. The regions defined by the AIB1 and PTPN1 genes (at 20q12 and 20q13.1, respectively) were amplified in 25% and 29% of the sporadic tumors, also without simultaneous coamplification of other regions. Amplification of AIB1 (asteroid receptor coactivator gene) was associated with estrogen receptor positivity in sporadic ovarian carcinomas (P = 0.01) and showed a tendency to correlate with poor survival of patients. Of the genes amplified in breast cancer, the BTAK gene was amplified in 21%, the MYBL2 gene in 17%, and the ZNF217 gene in 12.5% of the sporadic tumors. The high frequency of gene amplification at 20q12-q13.2 suggests that the genes amplified therein may play a central role in the pathogenesis of sporadic and hereditary ovarian carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0034025874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034025874&partnerID=8YFLogxK

M3 - Article

C2 - 10815905

AN - SCOPUS:0034025874

VL - 6

SP - 1833

EP - 1839

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 5

ER -